| pubmed-article:12186462 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12186462 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12186462 | lifeskim:mentions | umls-concept:C0025286 | lld:lifeskim |
| pubmed-article:12186462 | lifeskim:mentions | umls-concept:C0020402 | lld:lifeskim |
| pubmed-article:12186462 | lifeskim:mentions | umls-concept:C0242656 | lld:lifeskim |
| pubmed-article:12186462 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:12186462 | lifeskim:mentions | umls-concept:C1519810 | lld:lifeskim |
| pubmed-article:12186462 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:12186462 | pubmed:dateCreated | 2002-8-20 | lld:pubmed |
| pubmed-article:12186462 | pubmed:abstractText | The management of certain meningiomas of the skull base and those involving the dural venous sinuses remains a challenge. In recent reports it has been suggested that hydroxyurea chemotherapy can cause regression of unresectable and recurrent meningiomas. The authors report their experience in using hydroxyurea for the treatment of patients with recurrent or unresectable meningiomas. | lld:pubmed |
| pubmed-article:12186462 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12186462 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12186462 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12186462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12186462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12186462 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12186462 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:12186462 | pubmed:issn | 0022-3085 | lld:pubmed |
| pubmed-article:12186462 | pubmed:author | pubmed-author:AbreyLauren... | lld:pubmed |
| pubmed-article:12186462 | pubmed:author | pubmed-author:MacdonaldDavi... | lld:pubmed |
| pubmed-article:12186462 | pubmed:author | pubmed-author:HariharanSubr... | lld:pubmed |
| pubmed-article:12186462 | pubmed:author | pubmed-author:MasonWarren... | lld:pubmed |
| pubmed-article:12186462 | pubmed:author | pubmed-author:GentiliFredF | lld:pubmed |
| pubmed-article:12186462 | pubmed:author | pubmed-author:CruzCharlene... | lld:pubmed |
| pubmed-article:12186462 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12186462 | pubmed:volume | 97 | lld:pubmed |
| pubmed-article:12186462 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12186462 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12186462 | pubmed:pagination | 341-6 | lld:pubmed |
| pubmed-article:12186462 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:meshHeading | pubmed-meshheading:12186462... | lld:pubmed |
| pubmed-article:12186462 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12186462 | pubmed:articleTitle | Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. | lld:pubmed |
| pubmed-article:12186462 | pubmed:affiliation | Department of Medicine, Princess Margaret Hospital, and University of Toronto, Ontario, Canada. warren.mason@uhn.on.ca | lld:pubmed |
| pubmed-article:12186462 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12186462 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12186462 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12186462 | lld:pubmed |
